Low Testosterone and Cardiovascular Risk: What the TRAVERSE Trial Evidence Shows

Yes — low testosterone correlates with increased cardiovascular disease risk across multiple epidemiological studies. Mechanisms include visceral fat accumulation, insulin resistance, dyslipidemia, endothelial dysfunction, and chronic inflammation. Treating hypogonadism may reduce cardiovascular risk factors, though the TRAVERSE trial showed TRT neither increases nor decreases MACE over 33 months.

The 2023 TRAVERSE trial (5,200 patients) found no significant increase in major cardiovascular events (MACE) with TRT vs. placebo in high-cardiovascular-risk men, settling the long-running safety debate. The FDA removed the cardiovascular black-box warning from TRT labels. Remaining considerations: modestly higher atrial fibrillation rates and polycythemia risk (monitor hematocrit).

Low testosterone associates with metabolic syndrome — including hypertension — through visceral fat accumulation and insulin resistance. Testosterone directly influences arterial vasodilation via nitric oxide. Studies show TRT modestly reduces blood pressure in hypogonadal men with hypertension, possibly through improved insulin sensitivity and reduced visceral fat.

No — it means TRT does not increase the composite risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over the 33-month study period, which was the specific safety question the trial was designed to answer. It did find modestly higher rates of atrial fibrillation and a trend toward more pulmonary embolism and polycythemia-related events, which is why ongoing monitoring (hematocrit checks, awareness of AF symptoms) remains part of responsible TRT management rather than something the trial made unnecessary.

This remains less definitively established than the safety question TRAVERSE answered. TRT does measurably improve several cardiovascular risk factors — reducing visceral fat, improving insulin sensitivity, and in some studies modestly lowering blood pressure — which theoretically should translate to lower long-term cardiovascular risk. However, TRAVERSE was designed to test safety (whether TRT increases MACE), not to test whether it actively reduces cardiovascular events beyond placebo, and it did not find a protective benefit on that composite endpoint either. The most accurate current summary is that TRT improves several individual risk factors without yet having definitive trial evidence of reducing actual cardiovascular events.

No — testosterone testing itself carries no risk and can be valuable information regardless of cardiac history, since low testosterone's association with worse cardiovascular risk factors makes identifying and, where appropriate, addressing it potentially beneficial for overall risk management. The more nuanced question is whether TRT specifically should be started, which is a separate decision from testing, and one that benefits from cardiology input in men with significant existing heart disease, particularly around timing relative to any recent cardiac event.

Baseline and periodic hematocrit checks are the most important routine monitoring point, since polycythemia is the most actionable and well-documented cardiovascular-adjacent risk from TRT. Blood pressure should also be tracked, since testosterone can have variable effects on it. Men with existing cardiac risk factors or a history of atrial fibrillation should discuss symptom awareness (palpitations, irregular heartbeat) with their prescriber so any new AF episode is caught and evaluated promptly rather than dismissed. None of this requires unusually intensive monitoring beyond what's already standard practice for responsible TRT management.

The concern traces largely to earlier, smaller observational studies in the 2010s that found associations between TRT use and cardiovascular events, which prompted an FDA safety communication and black-box warning even though those studies had significant methodological limitations, including confounding by indication (sicker men were often the ones prescribed TRT in the first place). TRAVERSE was specifically designed as a large, rigorous, randomized trial to definitively answer the question those flawed observational studies couldn't, which is why its findings carried enough weight to prompt the FDA to remove the warning it had previously required.

Age itself isn't a contraindication given TRAVERSE's findings, since the trial specifically enrolled higher-risk, older men and found no increased MACE risk in that population. What matters more than age alone is the presence and severity of specific cardiac risk factors and conditions — a thorough cardiovascular assessment before starting TRT, including relevant history and baseline labs, remains sound practice for any man with meaningful risk factors regardless of exact age, rather than applying an arbitrary age cutoff.

TRAVERSE was a large, prospective, randomized, placebo-controlled trial specifically designed to test cardiovascular safety, enrolling over 5,000 men who already had cardiovascular disease or elevated cardiovascular risk — precisely the population where safety concerns mattered most. This design avoids the confounding-by-indication problem that plagued earlier observational studies, where the reasons a man was prescribed TRT (rather than TRT itself) may have been driving the observed associations with cardiovascular events. Randomization ensures the treatment and placebo groups were otherwise comparable, isolating TRT's actual effect on cardiovascular outcomes far more reliably than observational data ever could.